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Benzothiazole is a heteroaromatic compound known for its wide range of 
bioactivities including anti-cancer, anti-viral, anti-microbial, anti-inflammatory, anti-
convulsant, anti-diabetic, anti-helminthic, and anti-tubercular activities. Research has 
shown that derivatives of benzothiazole exhibit inhibition of proliferation via apoptosis in 
various human cancer cell lines, such as liver cancer (Wang, et. al., 2011). In this study, a 
series of novel hybrid benzothiazole α-cyanostilbene derivatives and styrylbenzothiazole 
derivatives containing boronic acid and non-boronic acid pharmacophores were 
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synthesized. The anti-cancer and anti-invasive properties of selected benzothiazole α-
cyanostilbene derivatives on U-87MG glioblastoma cells were investigated in vitro.  
U-87MG cells were incubated with synthesized novel hybrid compounds at 
varying concentration to determine the lethal concentration 50 (LC50) of the compounds. 
All hybrid compounds displayed inhibitory effects on cell growth and the LC50 of the 
compounds varied depending on the nature of the pharmacophores. Moreover, 
compounds containing both boronic acid substituent and fluoro substituent exhibit lower 
LC50 than those that contain only one of the substituents. Cell motility has been 
investigated and we have found that was were no difference in motility between the 
treated and untreated cells. Results indicate anti-invasive properties in boronic acid and 
fluoro substituents at ortho position and boronic acid substituent at para position.  
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CHAPTER 1 
 
INTRODUCTION 
 
Overview of Research Project 
Cancer is one of the leading causes of death in the United States. Although 
glioblastoma multiforme (GBM) is not common in the overall cancer population it is one 
of the most lethal cancers, with a median survival of 12-15 months (Wen and Kesari, 
2008). GBM is a malignant brain tumor that arises from astrocytes characterized by 
invasive growth and proliferation. Unfortunately, it is also one of the most common type 
of brain tumors in adults.  
Glioblastoma is incurable due to its aggressive, rapid, invasive growth, and 
proliferation. At present, surgical removal of the malignant tumor, followed by systemic 
temozolomide chemotherapy and radiation therapy are used to treat GBM (Verhoeff et 
al., 2009). Despite the aggressive therapies, less than 5% of treated GBM patients survive 
5 years after treatment due to recurrence of GBM after surgical removal of the tumor; the 
recurrence of GBM is often within the marginal tissues of the surgical removal site 
(Gaspar et al., 1992). Furthermore, maximizing the treatment effects of chemotherapy, 
surgery, and radiation therapy on a widely dispersed disease such as GBM could lead to 
neurological impairment as well as a reduced quality of the patient’s life (Giese et al., 
2003).   
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However, with the increase in understanding of GBM on a molecular level, new 
therapeutic approaches have emerged. One possible novel therapeutic agent is 
benzothiazole, a heterocyclic compound known for its wide range of biological properties 
including anti-cancer activities, specifically anti-invasive properties (Ali and Siddiqui, 
2013; Hiyoshi et al., 2014). In this project, I have synthesized and determined whether 
novel hybrid benzothiazole derivatives can be used as anti-cancer and anti-invasion drugs 
for glioblastoma cells.  
 
Cancer 
Cancer is among the leading causes of death worldwide and it has a major impact 
on society. Humanity has been fighting cancer for centuries and while advancements are 
made, there is still no cure for most cancers. The American Cancer Society (2019) 
predicts that there will be 1,762,450 new cancer cases and about 606,880 Americans are 
expected to die of cancer in 2019.  
Cancer is a collection of 
diseases characterized by uncontrolled 
growth and the spread of abnormal cells 
which results from atypical gene 
expression and/or regulation, favoring 
cell proliferation. Hanahan and 
Weinberg (2000) established six traits, 
known as the hallmarks of cancer, shared by all forms of cancers. These include the 
stimulation of self-growth, resistance to anti-growth signals, the ability to multiply 
Figure 1 Hallmarks of Cancer. Six traits shared by 
all forms of cancers as established by Hanahan 
and Weinberg 
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indefinitely, resistance to apoptosis, the ability to sustain angiogenesis and the ability to 
invade and metastasize (Fig 1).  
While all of these traits play a role in cancer progression, invasion and metastasis 
constitute a vital role in the progression of cancer. Invasion occurs when the malignant 
cells migrate from the primary tumor mass to the local surrounding cells. The process of 
invasion begins with the detachment of the cancer cells from the original tumor mass. 
Subsequently, the tumor then secretes proteases which degrade the extracellular matrix. 
The cancer cells go through morphological changes where protrusions such as 
pseudopodia, lamellipodia, invadopodia and filopodia began to extend from the leading 
edge of the cell. These protrusions begin forming membrane anchors, contracting the 
cytoskeleton and allowing the cells to move forward (Nakada et al., 2007) (Fig. 2). 
 
Figure 2 Invasion Cascade. Invasion occurs when the cancer cells moves from the 
initial tumor mass and spread to local normal cells. The process of invasion 
involves four main steps: detachment from the original, degradation of 
extracellular matrix, formation of membrane protrusions, and migration. 
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Metastasis is the dissemination of tumor cells from the primary site to a distant 
secondary site (Fig 3). In metastasis, after penetrating through the extracellular matrix, 
the migrating cell must arrive at the lymphatic or vascular system. Subsequently, the 
migrating cell travels through the vascular/lymphatic system while evading the immune 
system. The migrating cell then exits from the circulation, colonizes and proliferates at a 
secondary site (Chan & Giaccia, 2007) (Fig. 3). 
        
 
 
 
 
 
 
 
 
Figure 3 Metastatic Cascade. Metastasis occurs when the tumor cells 
from the primary site spread to a secondary site.  
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Brain Cancer 
Brain cancer refers to the abnormal growth of cells in the brain. Although brain cancer is 
relatively rare, it is among the leading causes of cancer death. Common primary brain 
tumors include: glioma (tumor of the 
glial cells), meningiomas (tumor of the 
meninges), medulloblastoma (tumor of 
the neuroectodermal cells in the 
cerebellum), gangliogliomas (tumors of 
neurons and glial cells), and 
schwannomas (tumor of the Schwann 
cells).  
Gliomas refers to all tumors that begin in the glial cells and are classified by their 
structural appearances into three main groups: astrocytomas, oligodendrogliomas, and 
ependymomas (Fig. 4). While relatively rare, constituting only about 5% of all cancers, 
gliomas are the most proliferative.  (American Cancer Society, 2016).  
Astrocytomas are tumors that begin in the astrocytes. Astrocytes are star-shaped 
glial cells that play a vital role in a variety of tasks, such as synaptic support, axon 
guidance, maintenance of blood-brain barrier (Blackburn et al., 2009), maintenance of 
ionic homeostasis in glia (Simard & Nedergaard, 2004), and maintenance of synaptic 
homeostasis (Barbour et al., 1988). The interaction of astrocytes with neurons is essential 
for the growth of the dendritic cells, effective synapse formation, and the removal of 
unwanted synapses (Garwood et al., 2001). Astrocytomas make up about 80% of all 
malignant brain tumors (American Cancer Society, 2016). The World Health 
Figure 4 Classification of gliomas. Gliomas 
are classified by their structural appearances. 
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Organization has classified astrocytomas into four grades based on their malignancy and 
proliferation (Fig. 5). 
 
 
 
Glioblastoma Multiforme (GBM) 
Glioblastoma multiforme (GBM) is the most common type of glioma. It is 
extremely lethal due to its invasive growth and proliferative nature. The median survival 
period for GBM is 12-15 months (Wen and Kesari, 2008).   
 Glioblastoma is incurable due to its aggressive and invasive growth, proliferative 
nature, and destructive malignancy. Currently, GBM is treated through surgical removal, 
followed by systemic temozolomide chemotherapy, and radiation therapy (Verhoeff et 
al., 2009). However, fewer than 5% of the patients survive GBM after the treatment due 
to recurrence of the tumor within the removal site. GBM also has poor prognosis as a 
result of its aggressive nature. Although GBM does not metastasize outside the brain, it is 
Figure 5 Classification of Astrocytoma: Astrocytomas are classified into four grades 
based on their proliferation and malignancy. 
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extremely successful in the invasion of surrounding normal brain cells. Understanding the 
mechanism of invasion and key players involved in invasion can lead to development of 
novel therapies for glioblastoma.  
One of the key players of glioblastoma invasion is the gene family of matrix-
metalloproteinases (MMPs) which degrade the extracellular matrix proteins, creating a 
path for glioblastoma cells to invade surrounding normal brain tissues (Nakada et al., 
2003). Several MMPs have been shown to play in important role in cell migration not 
only in central nervous system (CNS) but also in cell types outside the CNS. Ogier et al. 
(2006) have shown that the constitutive expression of MMP-2 was observed in astrocyte 
migration while MMP-9 expression was nearly undetectable. However, these two MMPs 
(MMP-2 and MMP-9) have been shown to be highly upregulated in glioblastoma cells 
and were correlated with increased invasion (Sawaya et al., 1996; Rao et al., 1996).  
Another key player is the ADAM (a disintegrin and metalloproteinases) gene 
family, a family of multidomain membrane-anchored proteins that also play an important 
role in the invasion of glioblastoma cells. In normal cells, the members of the ADAM 
family play an important role in cell adhesion and cell fusion events and are often highly 
expressed in the brain, sperm and testis (Novak, 2004). Two ADAM members (ADAM-
12 and ADAM-17) aid glioblastoma cells to invade neighboring tissues. ADAM-17 
cleaves CD44, an adhesion molecule which binds to an extracellular matrix component 
(hyaluronic acid) and maintains cellular functions such as apoptosis, cell migration and 
proliferation (Takamune et al., 2007; Ponta et al., 2003). ADAM 12 has been directly 
correlated with proliferative activity and have been shown to be selectively expressed in 
glioblastoma cells (Kodama et al., 2004). At present, there is no cure for glioblastoma. 
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However, a better understanding of molecular mechanisms underlying the invasion of 
glioblastoma offers the hope of developing novel therapies. 
 
History of Drug Discovery 
In the past, drug discovery has depended heavily on random screening. In 
addition, the designing of novel drugs was based on the notion of a disease involving one 
target (Gediya and Njar, 2009). While this has led to the discovery of numerous novel 
drugs, the rate of drug discovery has decreased in recent years because new treatment 
regimens are increasingly difficult to identify (Bolognesi and Cavalli, 2016). In recent 
years, however, there is a growing interest in drugs that could impact multiple targets 
simultaneously. Multi-targeted drugs can be more effective and less vulnerable to 
resistance by the diseased cells through attack on multiple fronts (Zimmerman et al., 
2007).  
One common multi-target drug therapy currently used in designing novel drugs is 
the combination drug approach. Combination drugs, also known as drug cocktails, are 
when two or more active pharmaceutical drugs are combined physically into a single 
dosage form (Gautam and Saha, 2008). Compared to the single-target drugs, combination 
drugs are less prone to drug resistance and have been used to control numerous complex 
disease systems such as cancer. In combination chemotherapy, drugs that work through 
different mechanisms of actions are used to decrease the possibility of resistance by 
cancer cells to the treatment.  
However, while combination drug therapy is highly effective, it also has multiple 
limitations. For example, in combination chemotherapy there is an increased likelihood 
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of side effects due to the increased number of drugs in the combination therapy. In 
addition, due to the number of drugs involved, it is often difficult to know which drug 
caused a specific side effect.  Moreover, some side effects result not from a single drug, 
but due to the drug interactions between the drugs involved in the therapy.  
In recent years, there is an increasing interest in the development of multi-
component drugs where two or more pharmacophores are covalently linked into one 
single drug. The notion of pharmacophore was first introduced by Ehrlich in 1909 as a 
“molecular framework that carries the essential features responsible for a drug’s 
biological activity” (Ehrlich, 1909).  However, in 1998, IUPAC further elaborated 
pharmacophores as “the ensemble of steric and electronic features that is necessary to 
ensure the optimal supramolecular interactions with a specific biological target structure 
and to trigger its biological response” (Langer and Hoffmann, 2006).  
The concept of hybrid molecules was initially developed for the treatment of 
malaria. However, this strategy has been applied to the treatment of multiple complex 
disease systems such as cancer. One of the first hybrid anti-malarial drugs was reported 
by Dechy-Cabaret et al. (2000), where artemisinin and chloroquine moieties were 
covalently linked into one single molecule, trioxaquine. Trioxaquine has the properties of 
both artemisinin (alkylating heme) and of chloroquine (blocking polymerization). In 
2009, Cavalli and Bolognesi designed a novel compound for combating Trypanosoma 
and Leishmania (Cavalli and Bolognesi, 2009).  
Perhaps, the first hybrid drug and the only anti-cancer hybrid drug that's been 
used clinically is estramustine (Gediya and Njar, 2009). Estramustine was initially 
developed for the treatment of advanced prostate carcinoma (Jonsson et al., 1977) in 
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1977. However, over the years, it has been combined with other chemotherapeutic drugs 
to treat other forms of cancer such as glioblastoma multiforme (Piepmeier et al., 1993). 
Hybrid drugs can be classified according to the type of linkage between the 
pharmacophores (Fig 6). Directly linked hybrid drugs are attached by the functional 
group of each pharmacophore which often results in an ester, a carbamate or an amide 
that can be hydrolyzed enzymatically (e.g. lactandrate).   
Spacer linked hybrid drugs are classified as either cleavable or non-cleavable. 
Cleavable spacer linked hybrid drugs often contain ester linkages that can be cleaved by 
the plasma esterases (e.g. NO-aspirin). This releases the two pharmacophores which act 
independently. Non-cleavable spacer linked hybrid drugs contain a stable (in terms of 
chemical and enzymatic) linkage that cannot be hydrolyzed (e.g. estradiol-anilin 
mustard).  
Merged/overlapped hybrid drugs contain pharmacophores that are overlapped 
structurally and may retain the functional properties of both or either of the overlapped 
drugs (e.g azatoxin). Hybrid drugs are often synthesized from drugs that have already 
been developed. This is known as a post hoc approach. Another design of hybrids is 
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known as the ad hoc approach where scaffolds with liabilities such as instability in vivo 
are used for the synthesis of the hybrid drugs (Gediya and Njar 2009). 
 
The hybrid compounds synthesized in this project can be classified as the 
merged/overlapped hybrids. This 
classification was due to the fact that all 
synthesized hybrid compounds contain 
a stilbene pharmacophore upon which 
other pharmacophores are directly 
attached, merged or embedded (Fig 7).   
 
 
 
 
C 
A B 
D 
Cl 
Cl 
Figure 6 Example of types of hybrid drugs. A) Azatoxin B) Estradiol-Aniline Mustard C) NO-
Aspirin D) Lactandrate 
Figure 7 Example of synthesized compound. Blue: 
stilbene component, Red: Benzothiazole 
component, Yellow: cyano/nitrile component, 
Green: Boronic acid component 
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Novel Hybrid Benzothiazoles 
In recent years, heterocyclic compound analogs and derivatives have been studied 
extensively due to their potential as new therapeutic agents against cancer. Heterocyclic 
compounds are cyclic rings with one or more different elements and they contain either 
nitrogen, oxygen, or sulfur within the ring. Heterocyclic compounds have been reported 
to display biological activities such as anti-fungal, anti-inflammatory, anti-convulsant, 
herbicidal and anti-cancer (Saini et al., 2013). Due to their wide range of biological 
activities, heterocyclic compounds can be found in a majority of medical and 
pharmaceutical drugs. An example of one heterocyclic compound that is currently used 
as a treatment for glioblastoma is temozolomide, . Heterocyclic compounds exist in two 
forms: aromatic and non-aromatic (Fig. 8). Heteroaromatic compounds are flat molecules 
that contain alternating double and single bonds and obey Hückel's rule (4n + 2 π 
electrons). Hetero non-aromatic compounds are those that do not contain double bonds.  
Figure 8 Example of heteroaromatic (left) compounds and hetero non-aromatic (right) 
compounds. Heteroaromatic compounds contain double bounds while hetero non-aromatic 
compounds do not contain any double bounds.  
Benzothiazole is among these heterocyclic compounds, specifically 
heteroaromatic compounds, and has a wide range of biological activities including anti-
Hetero non-aromatic 
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tumor, anti-helmintic, analgesic, anti-diabetic, anti-malarial, anti-tubercular, anti-
inflammatory, anti-convulsant, and diuretic (Singh and Singh, 2014). Due to its 
aromaticity which makes the compound extremely stable, benzothiazole has been used as 
a scaffold to synthesize a large number of therapeutic agents (Ali and Siddiqui, 2013). 
Studies have shown the ability of benzothiazole derivatives to inhibit proliferation and 
invasiveness in breast cancer, colon cancer, and lung cancer (Hiyoshi et al., 2014; 
Mortimer et al., 2005; Wang et al., 2011); but to my knowledge, no published studies 
have investigated the therapeutic use of benzothiazole derivatives on glioblastoma.  
One of the goals for this study is to synthesize novel hybrid benzothiazole 
compounds. One specific functional group of interest to hybridize with the benzothiazole 
is boronic acid. Boronic acids are compounds containing boron and two hydroxyl (-OH) 
groups and they have been shown to display bioactivities such as anti-cancer, anti-
microbial, and anti-viral (Trippier and McGuigan, 2010).  Due to their unique structural 
features, boronic acids have been used to develop potent enzyme inhibitors, as antibody 
mimics that recognize biologically important saccharides, and boron neutron capture 
agents for cancer therapy (Yang et al., 2003). Consequently, there is a growing interest in 
boronic acid containing drugs. Currently, there are only two FDA approved boronic acid 
containing drugs. Among them is bortezomib (Velcade®), used for the treatment of 
relapsed multiple myeloma and mantle cell lymphoma (Trippier and McGuigen, 2010).   
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Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid 
Benzothiazoles 
Lipophilicity 
Lipophilicity plays an important role in the design and discovery of novel drugs. 
Lipophilic properties of a compound can be described using the octanol-water partition 
coefficient (LogP) which is the ratio of the concentration of the unionized molecule at 
equilibrium between aqueous and organic phases. Lipophilic compounds have the ability 
to dissolve in fats, oils, lipids and non-polar solvents. Lipophilicity is not synonymous 
with hydrophobicity. While hydrophobic compounds describe the interaction between the 
compound and water, lipophilic compounds interact with lipids. Lipophilicity of a 
compound affects its solubility, permeability, potency, selectivity, absorption, 
metabolism, and toxicity (Gao et al., 2017).  
 
Oral Bioavailability 
Oral bioavailability of novel hybrid benzothiazoles can be measured using 
Lipinski’s rule of five. This method of measurement is commonly used when new drugs 
are designed and developed, and the oral bioavailability of the potential drug molecule is 
unknown. According to Lipinski’s rule, the molecules would be orally active if: 1) the 
number of hydrogen-bond donors is less than five, 2) the molecular mass is less than 500, 
3) calculated octanol-water partition coefficient (Log P) is less than five, and 4) the 
number of hydrogen acceptors is less than ten. Drugs that are orally active generally do 
not violate any of the above rules. In addition to Lipinski’s rule of five, Veber et al. 
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(2002) added two more rules to improve the predictions of drug-likeness. They are as 
follows: 1) 10 or fewer rotatable bonds and 2) polar surface no greater than 140 Å. 
 
Blood-Brain Barrier Penetration 
Because the human brain is a 
highly sensitive and fragile neuronal 
organ system that requires high 
maintenance and regular supply of 
nutrients, fuels, and gases, the blood-
brain barrier  acts as a protective barrier 
that imposes various obstacles for 
foreign substances. The blood-brain 
barrier inhibits delivery of various 
therapeutic drugs and imposes an 
obstruction for delivery of a large number of drugs (Updahyay, 2014). The endothelial 
cells that make up the tight junction and their lack of fenestration preclude paracellular 
diffusion (Fig. 9). Therefore, the majority of drug blood-brain barrier penetration occurs 
through the passive diffusion through the cellular membrane (Pajouhesh and Lenz 2005).  
Here, I have investigated the potential therapeutic role of novel benzothiazole 
derivatives. In this study I have 1) predicted the bioavalability and the blood-brain barrier 
permeability of designed novel hybrid benzothiazoles, 2) synthesized novel hybrid 
benzothiazoles, and 3) determined the anti-cancer and/or anti-invasive properties of the 
novel compounds by treating U-87MG glioblastoma cells with these compounds. I 
Figure 9 Blood-brain barrier acts as a 
protective barrier that prevents the entry of 
various foreign substances.  
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hypothesize that benzothiazole containing compounds will inhibit the growth of U-87MG 
glioblastoma cells and exhibit anti-cancer/anti-invasive properties.  
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CHAPTER 2 
 
METHODOLOGY 
 
Candidate Novel Hybrid Benzothiazole Structures and Calculation of their 
Molecular Properties  
 The ChemSketch tool and Marvin JS by ChemAxon were used to draw all the 
hybrid molecules. Online server such as Molinspiration was employed to predict the 
biological properties of the tested hybrid molecules. .  Percent of absorption was 
calculated using the modified equation % absorption = 109 – 0.345 x TPSA from Zhao et 
al. (2002). All figures were drawn using softwares such as ChemDoodle and BioRender.  
 
Chemistry 
Materials 
The reagents and solvents used throughout the synthesis and analysis were 
commercially purchased from Sigma-Aldrich. The experiments were conducted under a 
conventional fume hood using a magnetic stirrer. IR spectra was obtained using Thermo 
Scientific Nicolet iS50 ATR Infrared Spectroscopy. NMR spectra was obtained using 
JEOL JNM-ECP400 FT NMR system, Eclipse400 FT NMR spectrometer, and Delta 
software.  
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Experimental Procedures 
Benzothiazole α-cyanostilbenes  
32 ml of water and 8 ml of ethanol was added into a clean and oven dried 50 ml 
round bottom flask containing a magnetic stir bar. After clamping the flask in place on a 
magnetic hot plate stirrer, the reagents 
were added in the following order: 1) 2.5 
mmol aromatic aldehyde containing or not 
containing boronic acid, 2) 2.5 mmol 
benzothiazole-2-acetonitrile, 3) 10 mmol 
of calcium oxide (CaO). This mixture was 
refluxed for three hours in a conventional 
fume hood (Fig 10). After the reflux 
reaction was completed, the mixture was 
placed into a beaker containing ice and 30 ml of saturated ammonium chloride (NH4Cl) 
and stirred on a magnetic stirrer until neutralization had taken place. Neutralization was 
established by measuring pH using litmus pH test strips. The neutralized mixture was 
vacuum-filtered and air-dried for up to 48 h (Fig 11). The 
resulting products were weighted and characterized by 
obtaining their IR and NMR spectra and comparing with 
the IR and NMR spectra of the organic starting materials.  
 After analyzing the products, they were further 
purified using extraction methods. The product was 
extracted three times. The resulting product was further 
Figure 10 Reflux setup 
was used to synthesize 
novel hybrid 
benzothiazole α-
cyanostilbenes  
Figure 11 Vacuum 
filter setup was used 
to separate the solid 
product from the 
mixture.   
Figure 12 Extraction and 
washing setup were used to 
purify the products to prevent 
the presence of CaO 
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purified by washing. Deionized water and saturated sodium 
chloride were used as inorganic solvents and ethyl acetate 
was used as the organic solvent (Fig 12). Ethyl acetate was 
then evaporated using the rotary evaporator (Fig 13) and the 
product was air dried overnight and analyzed using IR and 
NMR spectroscopy.  
 
Styrylbenzothiazole  
Preliminary tests were conducted to optimize synthesis of styrylbenzothiazoles. 
15 ml of fresh dry dimethylformamide (DMF) was syringed into an oven-dried 50 ml 
round bottom flask containing a magnetic stir bar. A CaCl2 drying tube was attached to 
the round bottom flask and the whole apparatus was clamped in place on a magnetic 
stirrer (Fig 14). The reagents were measured out and added to the flask in the following 
order: 1) 12.5 mmol lithium hydride, 2) 7.5 mmol potassium t-butoxide (KTB), 3) 2.5 
mmol aromatic aldehyde with subunits containing/not 
containing boronic acid. The mixture was stirred at 
room temperature for four hours in a conventional 
fume hood. At the completion of the reaction, the 
mixture was poured into a beaker containing ice and 
30 ml of saturated NH4Cl. The mixture was stirred for 
10 mins on a magnetic stirrer until neutralization had 
taken place. Neutralization was established by 
measuring pH using litmus pH test strips. After 
Figure 13 Rotary evaporator 
was used to remove the 
organic solvent 
Figure 14 Synthesis of 
styrylbenzothiazole was achieved 
by stirring the starting materials at 
room temperature  
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neutralization, the mixture was vacuum filtered and air dried overnight. The resulting 
products were weighted and characterized by obtaining their IR and NMR spectra and 
comparing with the IR and NMR spectra of the organic starting materials.  
 
Diagnostic IR and NMR Peaks 
IR spectroscopy was used to identify the novel hybrid compound and determined 
the presence and absence of the functional group in the mixture. NMR was used to 
further determine the molecular structure and the purity of the synthesized compounds. 
The following are the diagnostic IR and 1H NMR peaks expected to be observed in the 
synthesized compounds.  
 
Styrylbenzothiazole: 
Starting Materials: Methylbenzothiazole. The diagnostic IR peaks (cm-3) for 
methylbenzothiazole include: 1250-1020 (C-N), 1500-1400 (C-C aromatic), 3000-3100 
(C-H aromatic), 2850-3000 (C-H alkane). Diagnostic 1H NMR peaks for (δ) for 
methylbenzothiazole include: 3.0 (CH3), 7.5-8 (aromatic H), ~2.5 (H-C-N). 
Formylphenylboronic acid: The diagnostic IR peaks for formylphenylboronic acid 
include: 1710 (C=O aldehyde), 1300-1400 (B-O), 3200-3500 (O-H). For the 1H NMR 
spectrum, we should see peaks at 9.7-10 (C=O aldehyde), 7-8 (aromatic H), 2-5 (O-H). 
The disappearance of the methyl peak at 2850-3000 (C-H alkane) and of the 
aldehyde peak at 1710 (C=O aldehyde) from the IR spectrum and methyl peak at 3.0 
(CH3) and aldehyde peak at 9.7-10 (C=O aldehyde) from 1H NMR spectrum would 
indicate the formation of the desired product. In addition, we should see the formation of 
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C=C in the product which would be indicated by the peak at 1680-1640 from IR 
spectrum and ~7.0 from 1H NMR spectrum.  
 
Benzothiazole α-cyanostilbenes  
Starting Materials: Benzothiazoleacteonitrile. The diagnostic IR peaks of (cm-3) 
for benzothiazoleacetonitrile include: 2210-2260 (CN stretch), 1500-1400 (C-C 
aromatic), 3000-3100 (C-H aromatic), 2300-2000 (nitrile). Diagnostic 1H NMR (δ) peaks 
include: 2.0-3.0 (nitrile),7.5-8.0 (aromatic H). Formylphenylboronic acid: The diagnostic 
IR peaks for formylphenylboronic acid include: 1710 (C=O aldehyde), 1300-1400 (B-O), 
3200-3500 (O-H). For the 1H NMR spectrum, we should see peaks at 9.7-10 (C=O 
aldehyde), 7-8 (aromatic H), 2-5 (O-H). 
The aldehyde peak should disappear from both IR and 1H NMR if the desired 
product is formed. We should still see the nitrile peak at 2300-2000 for IR spectrum and 
at 2.0-3.0 for 1H NMR spectrum. In addition, the formation of C=C bond should be seen 
on both 1H NMR (~7.0) and IR (1680-160) spectrum if the product is present. 
 
Biology 
Maintaining U-87MG Glioblastoma Cell Line 
U-87MG glioblastomaa cells (ATCC) were grown and maintained in MEM 
(Minimum Essential Medium) supplemented with 10% fetal bovine serum (Gibco), and 
100U/ml penicillin/streptomycin solution (Gibco). The cells were kept in a humidified 
37˚C, 5% CO2 incubator. Every 48 h I observed the density of the cells in the plate, using 
a light microscope. When the density was low, the media was removed and replaced with 
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new media. However, when the density reached approximately 80%, the cell density was 
reduced by removing the old media and placing 2 ml of trypsin/EDTA (Gibco) on the 
cells for detachment, then removing half of the cells in the trypsin/EDTA solution, and 
lastly, adding 8 ml of new media to the plate.  
Compound Preparation 
 Stock samples were prepared to evaluate the cell viability after they were treated 
with novel hybrid benzothiazoles. This preparation was completed at least 24 h prior to 
the experiment. To prepare the samples, 0.02 g of novel compounds were dissolved in 1 
ml of dimethyl sulfoxide (DMSO). Previous studies in our lab have shown that 1% 
DMSO or less had no effect on cell viability.  
 Eight of the synthesized novel hybrid benzothiazole α-cyanostilbenes were 
selected for screening for their anti-cancer properties. These compounds were selected 
based on the heterocyclic subunit in the hybrid molecule containing boronic acid, non-
boronic acid (fluoro), or both (fluoro and boronic acid) at ortho, meta, and para positions. 
Focusing on these compounds will allow us to compare the effects of position on the 
aromatic ring, as well as the effects of boronic versus nonboronic acid compounds. These 
compounds were also compared to selected starting materials. 
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Treatment of U-87MG Glioblastoma Cells 
Novel hybrid compounds at varying concentration diluted in media (2.0 mg/ml, 
1.0 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 
mg/ml, 0.0625 mg/ml, 0.03125 mg/ml, 
0.015625 mg/ml, 0.0078125 mg/ml, 
0.003906 mg/ml, 0.001953 mg/ml) were 
placed in eleven wells of a CorningTM 
CostarTM flat bottom 12-well cell culture 
plate. The control well contained untreated 
cells that were only exposed to the cell culture media (Fig 15).  
 
Cell Viability Assay 
Preliminary tests were conducted to determine a suitable cell viability assay 
which accurately reflected the lethal concentration (LC50) of the novel hybrid 
compounds. A modified NIH cell viability assay was used to determine the effect of the 
novel hybrid compounds on U-87MG glioblastoma cell viability. The viability of U-
87MG cells was determined after the cells were treated with varying concentrations of 
novel hybrid compounds. U-87MG cells were introduced into a CorningTM CostarTM flat 
bottom 12-well cell culture plate at the concentration of 10,000 cells/well. The cell count 
was estimated using the trypan blue exclusion method (Gibco) and a hemocytometer.  
After the cells were introduced, they were placed into a humidified, 37˚C and 5% 
CO2 incubator for 24 h. Once the incubation period had elapsed, the cells were treated at 
varying concentration (2.0 mg/ml, 1.0 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 
Figure 15 12-Well Plate Setup 
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0.0625 mg/ml, 0.03125 mg/ml, 0.015625 mg/ml, 0.0078125 mg/ml, 0.003906 mg/ml, 
0.001953 mg/ml) of novel hybrid benzothiazoles and incubated for 24 h under the 
conditions mentioned above.  
At the end of the treatment period, the drug was removed, 1 ml of methanol was 
added to each of the wells and the cells were fixed for 5 mins. Methanol was removed at 
the end of the fixation, and crystal violet was added to the wells to stain the cells. The 
cells were then stained for 5 mins, washed and air-dried overnight. The stained cells were 
quantified using an inverted light microscope at 400x, with three individual fields per 
well counted and averaged (Fig 16). Each compound cell viability assay was repeated 
three times. The LC50 for each compound was determined using linear regression. 
 
 
 
 
Confirmation of Lethal Concentration (LC50) 
 To confirm that the LC50 values obtained from the cell viability assay were 
accurate, each calculated compound LC50 concentration was tested an additional nine 
times. The cells for each trial were obtained from new stock cultures. 50,000 cells were 
introduced in each of the 24 wells of a CorningTM CostarTM flat bottom culture plates and 
incubated for 24 h in a humidified, 37˚C, and 5% CO2 incubator. The cells were then 
treated with the LC50 of the novel hybrid benzothiazoles and incubated as above for 24 h. 
Figure 16 Cell Viability Assay Setup. Cells from the stock plate were introduced to the plate and 
was incubated. Cells were treated with compounds for 24hrs and were stained and counted.  
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At the end of the treatment, the cells were fixed and stained under the conditions 
mentioned above. 
 
Wound Healing Scratch Assay 
 A modified wound healing scratch assay was performed to determine the effect of 
the novel hybrid benzothiazoles on motility of the U-87MG glioblastoma cells. 200,000 
cells were introduced into 60 mm Thermo ScientificTM NuncTM Cell Culture dishes and 
grown in MEM supplemented with 10% FBS and 100U/ml penicillin/streptomycin. The 
cells were allowed to grow in a 5% CO2 humidified environment at 37°C until they 
reached 100% confluency as a monolayer (approximately 3 days). When the cells 
reached 100% confluency, a sterile 200 µl pipette tip was used to scratch the monolayer 
across the center of the dish (Fig 17). After creating the scratch, the media was gently 
removed via vacuum suction to remove the 
detached cells. The dish was then 
replenished with fresh medium in the 
control plate and test compounds at the 
lowest tested concentration (LTC) and the 
highest concentration that resembles the 
control (HCRC) plate (Table 1). Migration 
process was documented by taking sequential digital photographs of the ‘wound’ using 
the inverted light microscope. Digital photographs were taken every 24 h for two days. 
Each concentration was evaluated in triplicate.  
 
Figure 17 Scratch assay on 60mm dish. A 
scratch was made across the 100% confluent 
cell layer and were treated up to 24hrs.   
Scratch 
across the 
plate 
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Table 1 Concentrations Used for Wound Healing Scratch Assay 
Novel Hybrid Benzothiazole (mg/ml) 
 PKP2 PKP3 PKP4 PKP5 PKP6 PKP7 3F-
2BA 
4F-
3BA 
LTC  0.00195 0.00195 0.00195 0.00195 0.00195 0.00195 0.00195 0.00195 
HCRC 0.00195 0.00195 0.00195 0.00781 0.00781 0.00781 0.00195 0.00195 
*LTC = Lowest tested concentration; HCRC = Highest concentration that resembles the 
control  
Neurosphere Assay 
 The effect of the novel hybrid benzothiazoles on the site of tumor initiation 
(neurospheres) was determined by performing the neurosphere assay. In this assay, the 
cells were seeded in 24 wells CorningTM CostarTM flat bottom culture plates at a 
concentration of 50,000 cells per 500 µl, estimated by the trypan blue exclusion method.   
After introduction of the cells, the plates were incubated for 24 h in a 5% CO2 
humidified incubator at 37°C to allow for cell attachment. Once the 24 h had passed, the 
media was removed and replaced with the LC50 and the LTC of the tested compounds.  
The cells were treated with novel hybrid compounds for a total of six days at the 
conditions mentioned above (Fig 18). After 24 h of treatment, the media from day one 
cells of both treated and untreated wells were removed and the cells were fixed and 
stained under the aforementioned conditions. The plates were returned to the incubator 
until the next assay day. Fixing and staining methods were repeated at day 3 and day 6 of 
the treatment. Neurospheres were assessed by determining their number and size.  
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Invasion Assay 
Following the instructions from the CytoSelectTM Cell Ianvasion Assay Kit, U-
87MG cells were suspended in serum free media. Novel hybrid benzothiazoles at HCRC 
were added directly to the cell suspension. The cell suspension with the novel compounds 
were kept for 24 hours at 37˚C 5% CO2 in a humidified incubator to allow the invasive 
cells to pass through the basement membrane and cling to the bottom of the insert while 
the non-invasive cells stay in the upper chamber. After the incubation period, the non-
invasive cells were removed, and the invasive cells were stained. Stained invasive cells 
were quantified using the light microscope. The effect of the novel hybrid benzothiazoles 
on the invasiveness of GBM cells was analyzed by comparing the results of treated and 
untreated cells (Fig 19).      
Figure 18 Neurosphere Assay Setup. Cells were introduced and were treated at 
LC50 and HCRC of the tested compounds. Neurosphere formation was observed 
at the indicated time points.  
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Statistical Analysis 
 The significant difference between the concentrations and the control of each test 
compounds were calculated via one-way ANOVA with Dunette-adjusted post hoc test on 
IBM SPSS software. The significant difference of the invasion assay was determined via 
one-way ANOVA with Bonferroni-adjusted post hoc test on IBM SPSS software.  
  
Figure 19 Invasion assay principle based on CytoSelectTM Cell Invasion Assay Kit. 
Cells were suspended in the serum free media containing/lacking test compounds. 
The cells were incubated for 24hrs and invasive cells were quantified. 
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CHAPTER 3 
 
RESULTS 
 
Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid 
Compounds 
Molecular properties for novel hybrid benzothiazoles were calculated using an 
online software, Molinspiration (http://www.molinspiration.com// cgi-bin/properties) and 
the values are given in Table 2.  
 
Table 2 Predicted Molecular Properties of Novel Hybrid Benzothiazole Derivatives 
Compound LogP1 TPSA2 nAtoms3 nON4 nOHNH5 MW6 nRotB7 % ABS8 R59 
PKP2 3.00 77.14 22 4 2 306.15 3 82.38 Pass 
PKP3 2.77 77.14 22 4 2 306.15 3 82.38 Pass 
PKP4 2.97 77.14 22 4 2 306.15 3 82.38 Pass 
PKP5 3.89 36.68 20 2 0 280.33 2 96.34 Pass 
PKP6 4.11 36.68 20 2 0 280.33 2 96.34 Pass 
PKP7 4.09 36.68 20 2 0 280.33 2 96.34 Pass 
4F-3BA 2.91 77.14 23 4 2 324.14 3 82.38 Pass 
3F-4BA 2.88 77.14 23 4 2 324.14 3 82.38 Pass 
 
1. Octanol-water partition coefficient 
2. Topological polar surface area 
3. Number of atoms 
4. Number of hydrogen-bond acceptor 
5. Number of hydrogen-bond donor 
6. Molecular weight 
7. Number of rotatable bonds 
8. Percent absorption 
9.  Lipinski’s rule of five violation
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Chemistry 
 All benzothiazole α-cyanostilbenes products and styrylbenzothiazoles products 
were weighed and characterized by 1H NMR and IR spectroscopy. Data for the novel 
hybrid compounds are shown below.  
4-boronic acid-α-cyanobenzothiazolestilbene (PKP2) 
Yield: 115.6%; IR (ATR, cm-1):  2227 (C≡N stretch), 3364 (O-H), 1429 (B-O); 1H NMR 
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.8 (2H, d, Ar-H), 
8.2 (1H, s, CH) 
 
3-boronic acid-α-cyanobenzothiazolestilbene (PKP4) 
Yield: 108.8%; IR (ATR, cm-1):  2223 (C≡N stretch), 3120 (O-H), 1397 (B-O); 1H NMR 
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.5-8.0 (1H, m, Ar-
H), 8.2 (1H, s, CH) 
 
2-boronic acid-α-cyanobenzothiazolestilbene (PKP3) 
Yield: 73.03%; IR (ATR, cm-1):  2215 (C≡N stretch), 3134 (O-H), 1404 (B-O); 1H NMR 
(400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.5-8.0 (4H, m, Ar-H), 7.2-7.8 (1H, m, Ar-
H), 8.2 (1H, s, CH) 
 
2-fluoro-α-cyanobenzothiazolestilbene (PKP5) 
Yield: 87.9%; IR (ATR, cm-1):  3054 (=C-H), 2227 (C≡N stretch), 1241 (C-F); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.8 (1H, m, Ar-H), 8.0 (1H, s, 
CH) 
 
3-fluoro-α-cyanobenzothiazolestilbene (PKP7) 
Yield: 101.6%; IR (ATR, cm-1):  3057 (=C-H), 2218 (C≡N stretch), 1193 (C-F); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.1-7.3 (1H, m, Ar-H), 8.2 (1H, s, 
CH) 
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4-fluoro-α-cyanobenzothiazolestilbene (PKP6) 
Yield: 98.28%; IR (ATR, cm-1):  3054 (=C-H), 2227 (C≡N stretch), 1241 (C-F); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.4-7.5 (2H, d, Ar-H), 8.1 (1H, s, CH) 
 
3-(trifluoromethyl)- α-cyanobenzothiazolestilbene (PKP8) 
Yield: 98.20%; IR (ATR, cm-1):  (=C-H), 2234 (C≡N stretch), 1203 (C-F); 1H NMR (400 
MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.5-7.8 (2H, d, Ar-H), 8.2 (1H, s, CH) 
 
4-(trifluoromethyl)- α-cyanobenzothiazolestilbene (PKP9) 
Yield: 98.40%; IR (ATR, cm-1):  3061 (=C-H), 2234 (C≡N stretch), 1322 (C-F); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.7-7.8 (2H, d, Ar-H), 8.1 (1H, s, CH) 
 
2-chloro-α-cyanobenzothiazolestilbene (PKP10) 
Yield: 114.80%; IR (ATR, cm-1):  3042 (=C-H), 2226 (C≡N stretch), 751 (C-Cl); 1H 
NMR (400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.8 (1H, d, Ar-H), 8.0 (1H, 
s, CH) 
 
3-chloro-α-cyanobenzothiazolestilbene (PKP11) 
Yield: 89.90%; IR (ATR, cm-1):  3032 (=C-H), 2236 (C≡N stretch), 724 (C-Cl); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.5-8.1 (1H, d, Ar-H), 8.2 (1H, s, CH) 
 
4-chloro-α-cyanobenzothiazolestilbene (PKP12) 
Yield: 108.6%; IR (ATR, cm-1):  3032 (=C-H), 2221 (C≡N stretch), 758 (C-Cl); 1H NMR 
(400 MHz, Methanol-d3) δ: 7.4-7.8 (4H, m, Ar-H), 7.5-7.6 (2H, d, Ar-H), 8.1 (1H, s, CH) 
 
α-cyanobenzothiazole-2-thiophene-stilbene (PKP13) 
Yield: 108.60%; IR (ATR, cm-1):  3057 (=C-H), 2212 (C-S); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.3 (1H, d, Ar-H), 7.4 (1H, d, CH) 
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5-methyl-α-cyanobenzothiazole-2-thiophenestilbene (PKP14) 
Yield: 92.45%; IR (ATR, cm-1):  3059 (=C-H), 2225 (C-S); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.0-7.1 (1H, d, Ar-H), 7.4 (1H, d, CH), 2.3 (3H, 
s, CH) 
 
2-fluoro-5-boronic acid-α-cyanobenzothiazolestilbene (PKP15) 
Yield: 108.58%; IR (ATR, cm-1):  3032 (=C-H), 2221 (C≡N stretch), 1404 (B-O); 1H 
NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.5-7.6 (1H, d, 
Ar-H), 8.2 (1H, s, CH) 
 
2-fluoro-4-boronic acid-α-cyanobenzothiazolestilbene (PKP16) 
Yield: 101.58%; IR (ATR, cm-1):  3058 (O-H), 2218 (C≡N stretch), 1422 (B-O); 1H 
NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-7.9 (4H, m, Ar-H), 7.4-7.7 (1H, d, 
Ar-H), 8.3 (1H, s, CH) 
 
4-fluoro-3-boronic acid-α-cyanobenzothiazolestilbene (4F-3BA) 
Yield: 116.60%; IR (ATR, cm-1):  3350 (O-H), 3058 (=C-H), 2218 (C≡N stretch), 1422 
(B-O); 1H NMR (400 MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.6-
7.7 (1H, d, Ar-H), 8.1 (1H, s, CH) 
 
3-fluoro-2-boronic acid-α-cyanobenzothiazolestilbene (3F-2BA) 
Yield: 49.78%; IR (ATR, cm-1):  3350 (O-H), 1411 (B-O), 1234 (C-F); 1H NMR (400 
MHz, Methanol-d3) δ: 2.0 (1H, s, OH), 7.4-8.0 (4H, m, Ar-H), 7.2-7.5 (1H, d, Ar-H), 8.2 
(1H, s, CH) 
 
4-chloro-styrylbenzothiazole (PKP17) 
Yield: 94.45%; IR (ATR, cm-1):  3054 (=C-H), 752 (C-Cl); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
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3-chloro-styrylbenzothiazole (PKP18) 
Yield: 97.80%; IR (ATR, cm-1):  3052 (=C-H), 755 (C-Cl); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-7.9 (4H, m, Ar-H), 7.3-7.5 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
 
2-chloro-styrylbenzothiazole (PKP19) 
Yield: 89.90%; IR (ATR, cm-1):  3054 (=C-H), 752 (C-Cl); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
 
2-fluoro-styrylbenzothiazole (PKP20) 
Yield: 72.90%; IR (ATR, cm-1):  3057 (=C-H), 1234 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
 
3-fluoro-styrylbenzothiazole (PKP21) 
Yield: 97.60%; IR (ATR, cm-1):  3052 (=C-H), 1246 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.0-7.4 (1H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
 
4-fluoro-styrylbenzothiazole (PKP22) 
Yield: 97.80%; IR (ATR, cm-1):  3039 (=C-H), 1223 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.6 (2H, d, Ar-H), 7.3-7.4 (1H, d, CH) 
 
2-(trifluoromethyl)-styrylbenzothiazole (PKP23) 
Yield: 82.77%; IR (ATR, cm-1):  3053 (=C-H), 1102 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.2-7.7 (1H, d, Ar-H), 7.3-7.6 (1H, d, CH) 
 
3-(trifluoromethyl)-styrylbenzothiazole (PKP23 
Yield: 91.1%; IR (ATR, cm-1):  3059 (=C-H), 1117 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.7 (2H, d, Ar-H), 7.3-7.5 (1H, d, CH) 
 
4-(trifluoromethyl)-styrylbenzothiazole (PKP24) 
Yield: 81.00%; IR (ATR, cm-1):  3060 (=C-H), 1322 (C-F); 1H NMR (400 MHz, 
Methanol-d3) δ: 7.4-8.0 (4H, m, Ar-H), 7.4-8.0 (1H, d, Ar-H), 7.3-7.4 (1H, d, CH) 
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 Table 3 shows the structures of the reactants and the products in details. 
Benzothiazole α-cyanostilbenes were obtained in yields ranging from 49.78% to 
116.60%, with the substituent 3-fluoro-2-formylphenylboronic acid having the lowest 
yield and the substituent 4-fluoro-3-formylphenylboronic acid having the highest yield. 
Overall, functional groups that are ortho-substituted have lower percent yield compared 
to those that are meta- and para-substituted, with the exception of the 
chlorobenzaldehyde substituents. 
 Styrylbenzothiazoles were obtained in yields ranging from 72.90% to 97.80%, 
with the substituent 2-fluorobenzaldehyde having the lowest yield and substituents 2-
chlorobenzaldehyde and 4-fluorobenzaldehyde having the highest yield. In this family, 
there seems to be no relationship between the substituents’ positions and the products’ 
yield. 
 
Table 3 Reactants and product structures 
2-Benzothiazole 
Reactant 
Aldehyde Reactant 2-Benzothiazole Product Percent 
Yield 
(%) 
-Acetonitrile 
 
 ɑ-Cyanostilbenes  
4-formylphenolboronic 
acid 
 
 
    PKP2  
 
115.6 
 3-formylphenolboronic 
acid 
 
PKP4  
 
108.8 
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 2-formylphenolboronic 
acid 
 
PKP3  
 
73.03 
 2-fluorobenzaldehyde 
 
PKP5  
 
87.9 
 3-fluorobenaldehyde 
 
PKP7  
 
101.6 
 4-fluorobenzaldehyde 
 
 
 
 
 
PKP6 
 
 
 
98.28 
 3-(trifluoromethyl) 
benzaldehyde 
 
 
 
 
PKP8  
 
98.2 
 4-(trifluoromethyl) 
benzaldehyde 
PKP9  
 
98.40 
 2-chlorobenzadehyde 
 
PKP10  
 
114.80 
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 3-chlorobenzaldehyde 
 
PKP11 
 
 
 
102.80 
 4-chlorobenzaldehyde 
 
 
 
 
 
PKP12  
 
108.60 
 2-thiophene- 
carboxaldehyde 
 
PKP13  
 
108.60 
 5-methyl-2-thiophene- 
carboxaldehyde 
 
PKP14  
 
92.45 
 2-fluoro-5-
formylphenylboronic 
acid 
 
PKP15  
 
108.58 
 2-fluoro-4-
formylphenylboronic 
acid 
 
PKP16  
 
 
101.94 
 4-fluoro-3-
formylphenylboronic 
acid 
4F-3BA 
 
 
 
116.60 
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 3-fluoro-2-
formylphenylboronic 
acid 
 
3F-2BA  
 
49.78 
-Methyl 
 
 Styryl  
4-chlorobenzaldehyde 
 
PKP17  
 
94.45 
 2-chlorobenzaldehyde 
 
  
 
97.80 
 3-chlorobenzaldehyde 
 
PKP18 
 
 
 
89.90 
 2-fluorobenzaldehyde 
 
PKP19 
 
 
 
72.90 
 3-fluorobenzaldehyde 
 
PKP20  
 
97.60 
 4-fluorobenzaldehyde 
 
 
 
 
 
PKP21  
 
97.80 
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 2-(trifluoromethyl)- 
benzaldehyde 
 
PKP22  
 
82.77 
 3-(trifluoromethyl)- 
benzaldehyde 
 
 
 
 
PKP23  
 
91.1 
 4-(trifluoromethyl)- 
benzaldehyde 
 
PKP24  
81.00 
 
Biology 
Cell Viability Assay 
The viability of U-87MG cells was determined after the cells were treated with 
varying concentrations of the novel hybrid benzothiazoles to establish their LC50 values. 
The LC50 values of the compounds were converted into µM from mg/ml (Table 4).  
Table 4 Tested compounds represented in µM 
TESTED COMPOUND LC50 (MG/ML) LC50 (µM) 
PKP2 0.08125 265.392  
PKP3 0.0625 204.14  
PKP4 0.03125 102.07  
PKP5 0.0625 280.33  
PKP6 0.09375 334.42  
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PKP7 0.0875 312.13  
4F-3BA 0.01175 36.25  
3F-2BA 0.05625 173.53  
 
 Figure 20 shows the cell viability at all eleven concentrations and the red arrow 
indicates the LC50 of the compounds. Benzothiazoles containing boronic acid substituents 
at para, meta, and ortho positions are shown in Figure 20, A to C (PKP2, PKP4, PKP3). 
While all positions showed a reduction in cell viability, meta position had the lowest 
LC50 value (0.03125 mg/ml) and ortho position had the highest LC50 value (0.08125 
mg/ml).  
Figure 20, D to F (PKP6, PKP7, PKP5) shows the effects of benzothiazoles with 
fluoro substituents on U-87MG cell viability. All three positions showed a reduction in 
cell viability, with ortho position having the lowest LC50 value (0.0625 mg/ml) and para 
position having the highest LC50 value (0.09375 mg/ml). The results showed cell growth 
at the higher concentration (2 mg/ml to 0.5 mg/ml) PKP4 and PKP3. However, the cells 
did not look normal; they lacked the shape of glioblastoma cells and were round in shape.  
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 Treatment with benzothiazoles containing both fluoro and boronic acid 
substituents are shown in Figure 18, G and H (4F-3BA, 3F-3BA). Both compounds 
display decreases in cell viability. However, benzothiazole containing boronic acid at 
meta position and fluoro at para position of the boronic acid substituent had the lowest 
LC50 among all of the tested compounds.  
 The results of the novel hybrid compounds were compared with the effect of 
benzothiazole starting material (benzothiazole-2-acetonitrile) on cell viability. Figure 21 
shows the result obtained from the benzothiazole starting material. The LC50 value of the 
starting material (0.2 mg/ml) is approximately two times higher than the LC50 value of the 
tested compound with the highest LC50 value (PKP6).  
* 
Figure 20 The effect of novel hybrid benzothiazoles on U-87MG glioblastoma cell viability compared 
to untreated U-87MG cells. Red arrows indicate the LC50 values of each compound.  A: PKP2-
Boronic acid substituent at para position; B: PKP4-Boronic acid substituent at met position; C: 
PKP3-Boronic acid substituent at meta position. D: PKP6-Fluoro substituent at para position; E: 
PKP7-Fluoro substituent at meta position; F: PKP5-Fluoro substituent at ortho position; G: 4F-2BA-
Boronic acid substituent at meta position and fluoro substituent at para position to boronic acid 
substituent; H: 3F-2BA-Boronic acid substituent at ortho position and fluoro substituent at meta 
position to boronic acid substituent.  Asterisks represent the lowest concentration with a statistically 
significance difference from control p ≤ 0.05. Error bars indicate standard error, n = 3 independent 
experiments in triplicate. 
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Confirmation of Lethal Concentration (LC50) 
 To ensure that the LC50 values obtained from the linear regression using data from 
the cell viability assay were accurate, concentrations of each compound at the calculated 
LC50 values were verified with nine replicates. Figure 22 shows that while most 
compounds were within the 50% cell viability range, PKP2 was well below the range 
(27.7%).  
 
Figure 21 The effects of benzothiazole starting material on U-87MG glioblastoma 
cells compared to untreated U-87MG cells. Red arrow indicates the LC50 value of 
the starting material. Asterisk represents the lowest concentration with a 
statistically significant difference from control,  p ≤ 0.05. Error bars indicate 
standard error, n=3 independent experiments in triplicate. 
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As seen in Figure 22, the cell viability of PKP2 was much lower when U-87MG 
glioblastoma cells were treated nine times at the initial LC50 value. As a result, PKP2 was 
tested again using the modified NIH cell viability assay to redefine its LC50 value. Figure 
23 shows the new LC50 value (0.026561 mg/ml) obtained from linear regression.  
 
Figure 22 Confirmation of LC50 values for eight novel hybrid benzothiazole 
compounds. Cell viability was measured at the predicted LC50 for each of the 
eight novel hybrid benzothiazoles. Each bar represents the mean and standard 
error for nine independent replicates. 
Figure 23 Redefined LC50 of PKP2. U-87MG were treated with PKP2 following the 
modified NIH cell viability assay. Red arrow indicates the LC50 value of the 
compound. Error bars indicate standard error, n = 3 independent experiments in 
triplicate 
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Wound Healing Scratch Assay 
Analysis of cell migration via wound healing scratch assay was used to quantify 
the alterations in cell migratory capacity in response to treatment with novel hybrid 
benzothiazoles. The results however showed not migration but rather the present or 
absence of cells in the scratch. Figure 24 shows the results of untreated cells while Figure 
25 shows a representative plate of treated cells. Treated plates filled in the scratch at the 
same extent as the control plate.  
 
Neurosphere Assay 
 To determine the effect of the tested compounds on the formation of 
neurospheres, U-87MG cells were treated with the LC50 and LTC of each novel hybrid 
benzothiazoles (Table 1). Table 5 shows the neurosphere formation at LTC. While no 
significant difference between treated and untreated compounds seem to be present, 
PKP4, PKP5, and PKP6 showed the delay in the formation of neurospheres.  
Table 6 shows the neurosphere formation at the LC50. Neurospheres were absent 
day 1 for all compounds while two small neurospheres were present in the control. There 
were no neurospheres present at day 3 for all compounds with the exception of PKP4, 
Figure 24 Scratch Assay – Untreated.  
A) Day one B) Day two 
B 
Figure 25 Scratch Assay - Treated (PKP3) 
A) Day one B) Day two 
A B 
850 µm 
820 µm 
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PKP5, and PKP6 which had small neurospheres or the initial neurosphere formation 
(where U-87MG cells are beginning to form a neurosphere can be observed), while two 
medium neurospheres were present in the control. On day 6, PKP2, PKP5, and PKP7 had 
neuropsheres that were beginning their formation, PKP3 and PKP6 lacked neurospheres, 
and 4F-3BA, 3F-2BA and PKP4 had one small neurosphere. In contrast, the whole well 
was covered with neurospheres in the control.  
 
Table 5 Effect of Novel Hybrid Benzothiazoles on Formation of Neurosphere at Lowest 
Tested Concentration  
 DAY 1 DAY 3 DAY 6 
PKP2 +, starting +, medium +, large 
PKP3 +, starting + +, small +, large 
PKP4 Absent +, small +, medium 
PKP5 Absent +, medium +, large, +, small 
PKP6 Absent +, small-medium +, medium, + +, small 
PKP7 +, starting +, small +, large, +, small 
4F-3BA +, small +, medium Whole well covered 
3F-2BA +, small +, medium +, large 
CONTROL  +, small +, medium Whole well covered 
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Table 6 Effect of Novel Hybrid Benzothiazoles on Formation of Neurosphere at LC50 
COMPOUND + LC50 DAY 1 DAY 3 DAY 6 
PKP2 (0.02656 MG/ML) Absent Absent +, starting 
PKP3 (0.03215 MG/ML) Absent Absent Absent 
PKP4 (0.0625 MG/ML) Absent +, starting +, small 
PKP5 (0.0625 MG/ML) Absent +, small +, starting 
PKP6 (0.09375 MG/ML) Absent +, small Absent 
PKP7 (0.0875 MG/ML) Absent Absent +, starting 
4F-3BA (0.01171 MG/ML) Absent Absent +, small 
3F-2BA (0.05625 MG/ML) Absent Absent  +, small 
CONTROL + +, small + +, medium Whole well 
covered 
 
 
 
 
Figure 26 Representation of the sizes and description of neurosphere formation. 
Red line for scale.  
500 μm 
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Invasion Assay 
 To determine the anti-invasive properties of the tested compounds, U-87MG cells 
were treated with HCRC (Table 2). Figure 24 shows the effect of the tested compounds 
on the cell’s invasive properties. PKP2 and PKP3 both possessing boronic acid 
substituents at the para or meta positions and PKP5 which contain fluoro substituent at 
ortho position display a statistically significant decrease in the percentage of invasive 
cells. While PKP4, PKP6, and PKP7 display a decrease in the number of invasive cells, 
the differences are not statistically significant.  
 
 
  
Figure 27 Anti-invasive property of tested compounds. U-87MG cells were 
treated with six compounds at their HCRC values. Statistically significant 
difference (P ≤ 0.05 for one-way ANOVA) between untreated cells and tested 
compounds are indicated by an asterisk. Error bars indicate standard error, n= 3 
individual experiments done in duplicate wells for each experiment. 
* 
* 
* 
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CHAPTER 4  
 
DISCUSSION 
 
Predicted Bioavailability and Blood-brain barrier Permeability of Novel Hybrid 
Benzothiazoles 
Lipophilicity 
As discussed, lipophilicity of a compound plays an important role in the 
bioavailability and blood-brain barrier permeability. Higher lipophilicity has been shown 
to allow higher permeability in the gastrointestinal tract and across the blood-brain barrier 
(Winiwarter et al., 2007). However, if the lipophilicity is too high (LogP>5), this could 
result in high metabolic turnover, low solubility, and poor oral absorption as well as 
toxicity from inappropriate target interactions. Low lipophilicity, on the other hand, could 
also affect negatively on potency and permeability of a compound which results in 
reduced/poor bioavailability and efficacy. Compounds with LogP less than 4 and greater 
than 1 has been shown to have optimal physicochemical properties for oral drugs (Gao et 
al., 2016). As shown in Table 1, novel hybrid benzothiazoles are all highly lipophilic.  
However, while most compounds fall within the range of LogP value with the optimal 
physicochemical properties, PKP6 and PKP7 are slightly above the optimal range. 
Therefore I believe all tested compounds, with the exception of PKP6 and PKP7, will 
most likely have the optimal physicochemical properties for oral drugs.   
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Oral Bioavailability 
The number of hydrogen-bond donor (nOHNH) for all novel hybrid 
benzothiazoles are well below 5 and are in accordance with Lipinski’s rule. All novel 
hybrid benzothiazoles have molecular weight of less than 500 which would allow them to 
be easily transported, diffused and absorbed as compared to those that are greater 500. 
LogP, as mentioned previously, determines the lipophilicity of novel hybrid 
benzothiazoles. All novel hybrid benzothiazoles have been shown to have LogP values 
that are less than 5, in accordance with Lipinski’s rule. The number of hydrogen-bond 
acceptors for all novel hybrid benzothiazoles is less than 10. None of the novel hybrid 
benzothiazoles violated Lipinski’s rule.  
Moreover, novel hybrid benzothiazoles meet the two additional extensions of 
Lipinski’s rules. All three types have less than 10 rotatable bonds and their topological 
polar surface area (TPSA) values range from 53-77 Å. TPSA has been correlated with 
hydrogen bonding of the molecules and is a reliable indicator of the bioavailability, 
gastrointestinal absorption, and blood-brain barrier penetration of a compound. Using the 
TPSA I calculated the percent absorption using the equation provided by Zhao et al. 
(2002). The calculated percent absorption for novel hybrid benzothiazoles ranged 
between 82.38-96.34%, indicating good oral bioavailability.  
 
Blood-brain Barrier Penetration 
Blood-brain barrier penetration properties of a compound can be predicted using 
the quantitative structure-activity relationship (QSAR). Hansch and Fujita (1964) have 
shown that the critical components for the blood-brain barrier penetration include 
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lipophilicity, hydrogen bonding, and molecular weight. Generally, compounds that are 
moderately lipophilic can cross the blood-brain barrier through passive diffusion. As 
mentioned above, lipophilicity of a compound can be determined by LogP. Pike (2009) 
has shown that the blood-brain barrier penetration is optimal when the LogP values are 
within the threshold of 2-3.5.  
Molecular weight is another critical component for blood-brain barrier (BBB) 
penetration. Compounds with a molecular weight less than 450 is needed to facilitate 
BBB penetration and lower for better oral absorption (Atkinson et al., 2002). Hydrogen 
bonding properties of a compound can also play a significant role in the CNS uptake 
profile. Polar molecules are often poor CNS agents, unless they are transported across the 
CNS by active transport (Pajouhesh and Lenz, 2005).  Polar surface area (PSA) has also 
been used to predict BBB penetration. Generally, compounds with lower PSA have been 
shown to be more effective at penetration of the BBB. The optimal PSA for BBB 
penetration has been estimated at 60-70 Å through 90 Å (Mouritsen and Jorgensen, 
1998).  
Based on the LogP values, all novel hybrid benzothiazoles, except for those with 
just fluoro substituents (PKP5-7) fall within the optimal blood-brain barrier penetration 
threshold. According to the previous studies, the BBB penetration is optimal within the 
LogP value range of 2-3.5. The LogP values of novel hybrid benzothiazoles ranges 
between 2.77-4.11. PSA values of all tested novel hybrid benzothiazoles, except for those 
with only fluoro substituent (PKP5-7), fall within the estimated optimal PSA range. In 
terms of molecular weight, all of novel hybrid benzothiazoles meet the condition to 
facilitate the BBB penetration; they are all less than 450.  
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Chemistry 
 Benzothiazole α-cyanostilbenes synthesis was achieved via base-catalyzed 
Knoevenagel condensation reaction. Knoevenagel condensation reaction is a nucleophilic 
addition of an active hydrogen atom to a carbonyl group, aldehyde in this specific 
reaction, with a base catalyst (Jones, 2011). This addition is then followed by elimination 
of a water molecule through the dehydration reaction (Fig 27).  
 
 The design and synthesis of benzothiazole α-cyanostilbenes were focused on 
covalently linking benzothiazole-2-acetonitrile and an aromatic aldehyde with or without 
boronic acid substituents to produce novel hybrid molecules. Various functional groups 
such as boronic acid, fluoro, chloro at ortho, meta, or para positions were synthesized for 
Figure 27 Mechanism of Knoevenagel Condensation reaction which occurs in the 
synthesis of hybrid benzothiazole a-cynanostilbene. Boronic acid substituent is used as 
an example. 
52 
 
comparison. Such comparisons are noted between PKP2, PKP3, PKP4, PKP5, PKP6, 
PKP7, 4F-3BA, and 3F-2BA. All of these compounds had a merged benzothiazole-
stilbene scaffold. However, PKP2, PKP3, and PKP4 have boronic acid substituent, 
whereas PKP5, PKP6, and PKP7 have fluoro substituent. 4F-3BA and 3F-2BA contain 
both boronic acid and fluoro substituents. Boronic acid was chosen as a substituent 
because of their success as FDA approved anti-cancer drugs (i.e. Ixazomib and 
Bortezomib). Fluoro substituents were chosen because of their ability to enhance a 
number of pharmacokinetic and physiochemical properties including enhanced 
membrane permeation and improved metabolic stability (Shah and Westwell, 2007).  
 Catalyst and solvent used in the process of Knoevenagel condensation reaction 
plays an important role in the percentage yield of the products. Evidences of the 
importance of the base catalyst can be seen in multiple studies with modified 
Knoevenagel reaction. For example, Rao and Venkataratnam (1991), utilized zinc 
chloride as a catalyst for their modified Knoevenagel condensation reaction and obtained 
products of good purity and high in yield. Schenider et al. (2015) reported the use of 
copper metal surfaces as their catalyst in their modified Knoevenagel reactions. Their 
study tested pure copper metal powder and compared it against carbon coated-copper 
nanoparticles (C/Cu) which has been shown to produce the highest activity in the 
Knoevenagel reaction (Koehler et al., 2009). Reactions catalyzed by pure metal powder 
showed higher yield and time efficiency. Panja et al. (2015) compared several different 
solvents for their Knoevenagel reactions such as the use of water, acetonitrile, 
dichloromethane, ethanol and solvent-free conditions. Their report indicated that the 
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solvent which optimized the reaction best was ethanol with the reaction time of 3 mins at 
room temperature and 98% yield.  
 In this project, calcium oxide was used as the base catalyst and ethanol and water 
were used as the solvents. The percentage yields obtained from the synthesis of the 
benzothiazole α-cyanostilbenes ranged from 49.78% to 116.60%. All benzothiazole α-
cyanostilbenes were synthesized under the same conditions (catalyst, solvent, and time). 
Based on the literature for optimizing percentage yields, it is possible to increase the 
compound with 49% yield. Varying reaction conditions such as reaction time, catalyst, 
and/or solvent could have resulted in increased percent yield of the product.  
 4F-3BA, with the highest percent yield of 116.60% and other compounds with 
percent yield over 100% could have produced higher yields due to the presence of 
impurities. The impurities in the product could have been the calcium oxide catalyst. 
These compounds were further purified by utilizing separation techniques and washing 
techniques in ethyl acetate as a solvent. All compounds that were purified had a decrease 
in percent yield by half of the initial percent yield. This may be the result of product loss 
during the purification process. Purification techniques which optimize product retention 
should be explored in future studies. Furthermore, changing the catalyst to calcium 
hydride or calcium hydroxide can decrease the presence of the catalyst in the product. 
Styrylbenzothiazole were synthesized using the aldol-type condensation reaction. 
Aldol-type condensation is the reaction of a stabilized carbanion ion and a carbonyl 
group which forms a β-hydroxyl (ketone/aldehyde) and water (Jones and Fleming, 2010). 
Figure 28 shows the general mechanism of Aldol-type condensation reaction which 
occurs in the synthesis of hybrid styrylbenzothiazoles.  
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 In the synthesis of styrylbenzothiazoles, no catalyst was used, and the reaction 
occurred at room temperature in four hours. While I was able to obtain products for 
chloro, fluoro, and trifluoromethyl substituents, I was unable to successfully produce 
products containing boronic acid substituents. In the initial experiment in the synthesis of 
styrylbenzothiazoles, I used dimethylformamide (DMF) as the solvent and potassium t-
butoxide (KTB) and lithium hydride (LiH) to deprotonate and to produce enolate ions. 
However, I obtained low percent yield for all the products and they were sticky in 
texture. To optimize the percent yield and to solve the texture problem, I opted for using 
just LiH without KTB. This produced better results. The percent yield obtained from the 
modified method ranged from 72% to 97%. However, I was not able to successfully 
synthesize styrylbenzothiazole containing boronic acid substituent. When analyzed under 
Figure 28 Mechanism of Aldol-type condensation reaction which occurs in the 
synthesis of hybrid styrylbenzothiazole. Boronic acid substituent is used as an 
example. 
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NMR and IR, the absence of boronic acid was noted. The cause of deboronation is still 
unknown and needs further exploration.  
 
Biological Evaluation 
In recent years, benzothiazole derivatives have been explored as potential new 
therapies with various biological activities against infection, osteoarthritis, and cancer 
(Bondock et al., 2010; Brantley et al., 2006; Vicini et al., 2011). Benzothiazole 
analogues, such as tetrahydrobenzothiazoles have been tested as potential anti-tumor 
drugs via inhibition of mutated p53 activity to enhance paclitaxel-induced apoptosis 
(Christodoulou et al., 2011). In addition, benzothiazole derivatives have been shown to 
produce cytotoxicity in human cancer cell lines in vitro (Kok et al., 2008) and act as 
potent growth inhibitors in a number of human-derived cancer cell lines (Hu et al., 2010; 
Tzanopoulou et al., 2010).  
 The results from this study confirm the biological activity of the novel hybrid 
benzothiazole structure. I have shown the potential anti-cancer effect of a new series of 
hybrid benzothiazoles in U-87MG glioblastoma cells. All tested compounds showed a 
decrease in cell viability. Based on the modified NIH cell viability assay, 4F-3BA, 
benzothiazole α-cyanostilbenes, containing both fluoro and boronic acid substituent on 
the aromatic ring, was the most effective compound tested (LC50: 36.25 μM), 
immediately followed by PKP2 which contains boronic acid substituent at para position 
(LC50:86.76 μM). This outcome could imply that fluoro-containing compounds had 
enhanced pharmacokinetic and physiochemical properties. Fluorines have been shown to 
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influence permeability and potency of compounds due to its high electronegativity and 
high lipophilicity (Gillis et al., 2015).  
Overall, there was no clear correlation between the potency of the compound and 
the substituent’s position on the aromatic ring. However, in compounds with boronic acid 
substituent, para position has the highest potency (LC50:86.76 μM) while ortho position 
had the lowest potency (LC50: 280.33 μM). In compounds with fluoro substituent, ortho 
position had the highest potency (LC50: 280.33 μM) and para position has the lowest 
potency (LC50: 334.42 μM). In general, compounds containing boronic acid substituents 
seem to favor the cytotoxic activity more than compounds containing fluoro substituents, 
since PKP2, PKp3, and PKP4 were more active than PKP5, PKP6, and PKP7.    
Neurospheres play an important role in multilineage differentiation in neural cells 
(Ishiguro et al., 2017). They are highly heterogeneous entities which produce the same 
cellular components of neural stem cells. Due to their abilities that mimic that of neural 
stem cells, they have been highly exploited in drug screening (Galli, 2013).  
In this project, U-87MG glioblastoma cells were treated with LC50 and LTC of the 
tested compounds to determine their effects on the formation of neurospheres. At the 
LTC, there appears to be no significant difference between treated and untreated 
compounds. However, PKP4, PKP5, and PKP6 seems to slightly decrease the formation 
of neurospheres compared to the other three tested compounds. Regardless, it does not 
take away from the fact that none of the compounds were able to significantly reduce 
neurosphere formation. At the LC50, there is a significant reduction of neutrosphere 
formation in treated compounds. All tested compounds appear to inhibit the formation of 
neurospheres at the same rate. This may be the result of 50% cell viability which prevents 
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the formation of neurospheres or the reduced number of neurospheres could be the cause 
of the reduced cell numbers and should be investigated further.  
As discussed in Chapter 1, one of the hallmarks of cancer is invasion and 
metastasis. Invasion and metastasis, in the context of GBM, plays a vital role in cancer 
progression and recurrence. None of novel hybrid benzothiazoles seems to inhibit or 
prevent cell migration as seen in the wound healing scratch assay. However, it is possible 
that the assay was not measuring the motility of the cells but instead their proliferation. 
Further modification of the assay is needed to be explored to accurately measure the 
migration of the cells. One area of modification could be the media used. By using serum 
free medium instead of serum containing fetal bovine serum, the assay could be made to 
measure only the migration of the cell.   
Three of the novel hybrid benzothiazoles (PKP2, PKP3, and PKP5) seem to 
decrease the number of invasive cells, as shown in the invasion assay. These three 
promising compounds warrant further detailed analyses to elucidate the underlying 
molecular mechanism of action. Moreover, due to the literature reports of benzothiazoles 
analogs with the abilities to induce apoptosis, novel hybrid benzothiazoles should be 
tested for the underlaying mechanism of the cause of cell death.  
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CHAPTER 5 
 
CONCLUSION 
 As disclosed in Chapter 1, glioblastoma multiforme is highly lethal due to its 
aggressive and invasive proliferation. A major factor shaping the high mortality lies in 
cancer cells’ ability to migrate and to proliferate. Therefore, development of cancer 
therapies targeting invasion and induction of apoptosis is necessary.   
In this study, 19 novel hybrid benzothiazole α-cyanostilbenes with or without 
boronic acid substituents and 7 novel hybrid styrylbenzothiazoles without boronic acid 
substituents were synthesized and described. Out of the total synthesized compounds, 8 
novel hybrid benzothiazole α-cyanostilbenes were screened for their anti-cancer 
activities. The result of the project demonstrated the anti-cancer activity of novel hybrid 
benzothiazole derivatives, particularly compound 4F-3BA, which had the highest potency 
in vitro.  
Based on the neurosphere assay, at LTC (0.00195 mg/ml) PKP4 (boronic acid at 
meta position), PKP5 (fluoro at ortho position), and PKP6 (fluro at para position) were 
the most successful compounds in delaying the formation of the neurospheres. At LC50 
all tested compounds were effective at preventing the formation of the neurospheres, with 
PKP4 (boronic acid at meta position) and PKP5 (fluoro at ortho position) being the least 
effective compounds.  
The result of the invasion assay showed that three compounds, PKP2 (boronic 
acid at para position), PKP3 (boronic acid at ortho position) and PKP5 ( display some 
anti-invasive properties. The anti-invasive properties of these three compounds should be 
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further evaluated by a more reliable invasion assay which utilizes Calcein fluorescence to 
quantify the number of invasive cells. All 8 tested compounds should be further tested to 
determine their effect on caspases to explore their potential as apoptotic inducing agents. 
In addition, all novel hybrid benzothiazoles should be further studied for their anti-cancer 
properties and verify the underlying mechanism of action.  
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Multiple Comparisons (PKP2) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
 
 
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -176.00000* 15.18273 .000 -221.0579 -130.9421 
1 mg/ml Control -176.00000* 15.18273 .000 -221.0579 -130.9421 
0.5 mg/ml Control -176.00000* 15.18273 .000 -221.0579 -130.9421 
0.25 Control -100.00000* 15.18273 .000 -145.0579 -54.9421 
0.125 mg/ml Control -97.89000* 15.18273 .000 -142.9479 -52.8321 
0.0625 Control -73.00000* 15.18273 .001 -118.0579 -27.9421 
0.03125 Control -19.89000 15.18273 .765 -64.9479 25.1679 
0.01562 Control -13.00000 15.18273 .972 -58.0579 32.0579 
0.00781 Control -35.66667 15.18273 .174 -80.7246 9.3912 
0.003906 Control -26.11000 15.18273 .483 -71.1679 18.9479 
0.00195 Control -3.44333 15.18273 1.000 -48.5012 41.6146 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP3) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -83.66767 38.93939 .249 -199.2284 31.8930 
1 mg/ml Control -133.77667* 38.93939 .018 -249.3374 -18.2160 
0.5 mg/ml Control -145.77667* 38.93939 .008 -261.3374 -30.2160 
0.25 Control -156.77767* 38.93939 .004 -272.3384 -41.2170 
0.125 mg/ml Control -121.33333* 38.93939 .036 -236.8940 -5.7726 
0.0625 Control -71.89000 38.93939 .404 -187.4507 43.6707 
0.03125 Control -66.44333 38.93939 .492 -182.0040 49.1174 
0.01562 Control -34.89000 38.93939 .963 -150.4507 80.6707 
0.00781 Control -42.78000 38.93939 .888 -158.3407 72.7807 
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0.003906 Control -42.44333 38.93939 .893 -158.0040 73.1174 
0.00195 Control -39.11333 38.93939 .929 -154.6740 76.4474 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP4) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -157.55333* 41.65868 .008 -281.1841 -33.9226 
1 mg/ml Control -154.11000* 41.65868 .009 -277.7407 -30.4793 
0.5 mg/ml Control -181.33333* 41.65868 .002 -304.9641 -57.7026 
0.25 Control -207.11000* 41.65868 .000 -330.7407 -83.4793 
0.125 mg/ml Control -182.77667* 41.65868 .002 -306.4074 -59.1459 
0.0625 Control -105.00000 41.65868 .126 -228.6307 18.6307 
0.03125 Control -102.11333 41.65868 .144 -225.7441 21.5174 
0.01562 Control -88.66667 41.65868 .257 -212.2974 34.9641 
0.00781 Control -79.11333 41.65868 .373 -202.7441 44.5174 
0.003906 Control -76.22000 41.65868 .413 -199.8507 47.4107 
0.00195 Control -33.77667 41.65868 .980 -157.4074 89.8541 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP5) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -187.66667* 34.29165 .000 -289.4342 -85.8991 
1 mg/ml Control -187.66667* 34.29165 .000 -289.4342 -85.8991 
0.5 mg/ml Control -166.77778* 34.29165 .001 -268.5453 -65.0102 
0.25 Control -160.33333* 34.29165 .001 -262.1009 -58.5658 
0.125 mg/ml Control -136.88889* 34.29165 .005 -238.6564 -35.1213 
0.0625 Control -95.77778 34.29165 .072 -197.5453 5.9898 
0.03125 Control -69.88890 34.29165 .299 -171.6565 31.8787 
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0.01562 Control -35.77777 34.29165 .914 -137.5453 65.9898 
0.00781 Control 14.55557 34.29165 1.000 -87.2120 116.3231 
0.003906 Control .88890 34.29165 1.000 -100.8787 102.6565 
0.00195 Control -9.22223 34.29165 1.000 -110.9898 92.5453 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP6) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -236.11000* 37.02171 .000 -345.9796 -126.2404 
1 mg/ml Control -235.00000* 37.02171 .000 -344.8696 -125.1304 
0.5 mg/ml Control -219.00000* 37.02171 .000 -328.8696 -109.1304 
0.25 Control -150.22333* 37.02171 .004 -260.0929 -40.3538 
0.125 mg/ml Control -124.22000* 37.02171 .021 -234.0896 -14.3504 
0.0625 Control -105.44667 37.02171 .065 -215.3162 4.4229 
0.03125 Control -44.11000 37.02171 .839 -153.9796 65.7596 
0.01562 Control -52.44333 37.02171 .693 -162.3129 57.4262 
0.00781 Control -11.44333 37.02171 1.000 -121.3129 98.4262 
0.003906 Control 28.55333 37.02171 .986 -81.3162 138.4229 
0.00195 Control 24.33333 37.02171 .996 -85.5362 134.2029 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP7) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -193.66667* 54.44449 .013 -355.2419 -32.0914 
1 mg/ml Control -192.89000* 54.44449 .014 -354.4653 -31.3147 
0.5 mg/ml Control -180.33333* 54.44449 .023 -341.9086 -18.7581 
0.25 Control -149.78000 54.44449 .079 -311.3553 11.7953 
0.125 mg/ml Control -109.88667 54.44449 .309 -271.4619 51.6886 
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0.0625 Control -58.44333 54.44449 .900 -220.0186 103.1319 
0.03125 Control -53.99667 54.44449 .934 -215.5719 107.5786 
0.01562 Control -32.33333 54.44449 .998 -193.9086 129.2419 
0.00781 Control -2.55433 54.44449 1.000 -164.1296 159.0209 
0.003906 Control 2.55667 54.44449 1.000 -159.0186 164.1319 
0.00195 Control -66.44333 54.44449 .822 -228.0186 95.1319 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (4F-3BA) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -117.77778* 17.11267 .000 -168.5632 -66.9924 
1 mg/ml Control -125.44445* 17.11267 .000 -176.2298 -74.6591 
0.5 mg/ml Control -127.44444* 17.11267 .000 -178.2298 -76.6591 
0.25 Control -129.11111* 17.11267 .000 -179.8965 -78.3257 
0.125 mg/ml Control -116.11111* 17.11267 .000 -166.8965 -65.3257 
0.0625 Control -80.44444* 17.11267 .001 -131.2298 -29.6591 
0.03125 Control -71.44444* 17.11267 .003 -122.2298 -20.6591 
0.01562 Control -80.33333* 17.11267 .001 -131.1187 -29.5479 
0.00781 Control -56.33334* 17.11267 .024 -107.1187 -5.5480 
0.003906 Control -41.66667 17.11267 .148 -92.4521 9.1187 
0.00195 Control -43.11110 17.11267 .126 -93.8965 7.6743 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (3F-2BA) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -151.55556* 25.28414 .000 -226.5915 -76.5196 
1 mg/ml Control -150.66667* 25.28414 .000 -225.7026 -75.6308 
0.5 mg/ml Control -147.66667* 25.28414 .000 -222.7026 -72.6308 
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0.25 Control -112.44444* 25.28414 .002 -187.4804 -37.4085 
0.125 mg/ml Control -83.55556* 25.28414 .024 -158.5915 -8.5196 
0.0625 Control -77.88889* 25.28414 .039 -152.9248 -2.8530 
0.03125 Control -60.44445 25.28414 .161 -135.4804 14.5915 
0.01562 Control -61.88890 25.28414 .145 -136.9248 13.1470 
0.00781 Control -48.44446 25.28414 .363 -123.4804 26.5915 
0.003906 Control -28.33334 25.28414 .878 -103.3693 46.7026 
0.00195 Control -40.11111 25.28414 .573 -115.1470 34.9248 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Multiple Comparisons (PKP2 revised) 
Dependent Variable:   Cells   
Dunnett t (2-sided)a   
(I) 
Concentration 
(J) 
Concentration 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
2 mg/ml Control -141.50000* 5.76749 .000 -160.0670 -122.9330 
1 mg/ml Control -141.33333* 5.76749 .000 -159.9003 -122.7664 
0.5 mg/ml Control -141.16667* 5.76749 .000 -159.7336 -122.5997 
0.25 Control -140.66667* 5.76749 .000 -159.2336 -122.0997 
0.125 mg/ml Control -141.00000* 5.76749 .000 -159.5670 -122.4330 
0.0625 Control -126.50000* 5.76749 .000 -145.0670 -107.9330 
0.03125 Control -53.50000* 5.76749 .000 -72.0670 -34.9330 
0.01562 Control -45.50002* 5.76749 .000 -64.0670 -26.9331 
0.00781 Control -43.49998* 5.76749 .000 -62.0669 -24.9330 
0.003906 Control -38.00000* 5.76749 .000 -56.5670 -19.4330 
0.00195 Control -39.16665* 5.76749 .000 -57.7336 -20.5997 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
 
 
 
